Reducing Adult Smoking: FDA Needs to Lead the Charge

Nov.28.2022
Reducing Adult Smoking: FDA Needs to Lead the Charge
US teen e-cigarette use declines, however, adult smoking still needs to see progress in reducing numbers.

Author Background: Dr. Matthew Holman is the Vice President in charge of regulatory strategy for PMI in the United States. Prior to joining Philip Morris in September, Holman served as the Director of the Office of Science at the FDA's Center for Tobacco Products.


Source: Duluth News Tribune, image provided by Matthew Holman.


The latest data from the National Youth Tobacco Survey tells a story that you may not have heard before. The U.S. Food and Drug Administration and Centers for Disease Control and Prevention recently released the results of the 2022 survey, which showed a decrease in underage e-cigarette use to levels below the "epidemic" announced by the FDA in 2018. The data shows a continued reversal of the trend.


According to the same data, the percentage of teenagers smoking combustible cigarettes is at its lowest historical level of 1.6%. In fact, over the past few years, there has been a significant decrease in the use of all tobacco products among adolescents. Many stakeholders, including myself, have tirelessly worked towards reducing underage usage and have achieved success.


However, according to data from the American Cancer Society, the decrease in the number of adult smokers has not matched this progress, with 34 million smokers currently in the United States.


The FDA could do more to help Americans quit smoking and should engage in conversations with smokers again, just like it did before releasing the 2018 Tobacco Survey results.


Smoking among adults has also decreased, although not significantly, much like among teenagers. According to public health data, smoking remains the largest single preventable cause of death in the United States. Therefore, while acknowledging the significant progress made in recent years in reducing tobacco use among youths is important, it is equally important to recognize that too many Americans still smoke.


As a senior professional at the FDA for 20 years and recently appointed as the top scientist for the agency's Center for Tobacco Products, I am aware that it is home to talented scientists who want to do more to help smokers make better choices than continuing to smoke - while also preventing underage nicotine use.


So, what can be done to speed up the reduction of adult smoking in the United States? The US public health agencies need to adopt a more balanced approach in promoting tobacco and nicotine products, which is an urgently needed and important strategic move.


The FDA has invested a significant amount of funds in launching multiple multimedia campaigns aimed at reducing underage electronic cigarette use among adolescents and parents. These efforts should continue. However, what is completely missing is similar investment in communicating with adult smokers. The FDA must engage smokers in a consistent, transparent, and meaningful way to help them quit smoking altogether or encourage those who don't quit to switch to innovative smoke-free products. The FDA acknowledges that such products are a better alternative to continuing smoking. Let's make sure adult smokers know this.


The message that all Americans need to hear from health experts is simple: if you don't currently use tobacco products, don't start. If you smoke, quitting is the best option. If you don't quit, switch to smoke-free alternatives. This message is scientifically supported, and the FDA's authorization of nicotine products confirms this. For adult smokers who completely switch to nicotine products, the chance of exposure to harmful chemicals in smoke is significantly reduced, and for certain products, the risk of lung cancer and other smoking-related diseases may be decreased.


Today, smokers are not receiving this crucial message, and that needs to change. Otherwise, nearly 500,000 Americans will continue to die unnecessarily every year. Health experts have a responsibility to proactively share information about better choices with adult smokers, while also continuing to prevent underage tobacco use.


When I was working at the FDA, Commissioner Scott Gottlieb announced a comprehensive plan aimed at getting smokers to switch from traditional combustible cigarettes to less harmful tobacco products or to quit tobacco altogether. The plan was unveiled over five years ago, but until now, the FDA's efforts have primarily focused on preventing underage use. It is now time to take action to assist adult smokers in making better choices.


I hope that my former colleagues at the FDA, who are all exceptional public health scientists, will take necessary action to accelerate the transition towards a healthier America by keeping smokers away from cigarettes.


Statement:


This article is sourced from compiled third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the accuracy of the content. The translation of this article is solely intended for industry communication and research.


Due to limitations in the translator's skills, the translated article may not accurately reflect the original text. Please consider the original text as the primary source.


2FIRSTS is fully aligned with the position and stance of the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
UK Vape Tax Reshapes Costs: VPZ's £1.5 Million Plan, Totally Wicked's Three HMRC Approvals and VSL's Wholesale Challenge
UK Vape Tax Reshapes Costs: VPZ's £1.5 Million Plan, Totally Wicked's Three HMRC Approvals and VSL's Wholesale Challenge
Britain's new vaping excise duty, introduced on October 1, 2026, is changing how manufacturers, distributors and retailers manage production, inventory and tax compliance. Specialist vape retailer VPZ reportedly plans to invest up to £1.5 million in production and duty-stamp systems, following earlier plans for a fifth production line, bonded warehousing and 40 additional stores. Rival Totally Wicked says it has obtained three HMRC approvals covering manufacturing, duty-suspended storage and representation of overseas manufacturers. Wholesale distributor Vape Supplier Limited (VSL) has identified stock conversion costs, warehousing requirements and margin pressure among its business risks. The companies illustrate how different operating models are responding to Britain's new tax and product-traceability requirements.
Market
Nov.16
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12